SML2617
Celiprolol hydrochloride
≥98% (HPLC)
同義詞:
Celiprolol hydrochloride, (3-[3-Acetyl-4-(3-t-butylamino-2-hydroxypropoxy)phenyl]-2,1-diethylurea hydrochloride, NSC 324509, REV 5320A, ST 1396, Selecor, Tenoloc
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C20H33N3O4 · HCl
CAS號碼:
分子量：:
415.95
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
推薦產品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
H2O: 2 mg/mL, clear
儲存溫度
2-8°C
InChI
1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
InChI 密鑰
VKJHTUVLJYWAEY-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
Celiprolol is a selective adrenoceptor modulator that acts not only as a selective β1 receptor antagonist, but also as a β2 receptor partial agonist. Because of its of its β2 agonist activity, celiprolol lacks the typical side effects of the beta-blockers, such as bronchoconstriction, depression of left ventricular function, and peripheral vasoconstriction, making it a good candidate for patients with both cardiovascular and pulmonary disease. It is currently being investigated for treatment of vascular Ehlers-Danlos Syndrome (vEDS).
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
James J Nawarskas et al.
Cardiology in review, 25(5), 247-253 (2017-07-26)
Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties
Jingjing Yu et al.
Journal of pharmaceutical sciences, 106(9), 2312-2325 (2017-04-18)
In recent years, an increasing number of clinical drug-drug interactions (DDIs) have been attributed to inhibition of intestinal organic anion-transporting polypeptides (OATPs); however, only a few of these DDI results were reflected in drug labels. This review aims to provide
Lawrence H Kwon et al.
Journal of hypertension, 35(9), 1768-1777 (2017-06-27)
Not only is there a limited number of studies on the effects of vasodilator β-blocker (VBB) therapy on kidney function - specifically, glomerular filtration rate (GFR), serum creatinine (sCr) and proteinuria - but of those that have been reported, the
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務